Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Targovax ASA ( (GB:0RIS) ) has provided an update.
Circio Holding ASA has completed a directed share issue of NOK 3.6 million at NOK 1.00 per share, following an oversubscribed rights issue and a parallel private placement, bringing total recent gross equity proceeds to approximately NOK 68.6 million. The board justified deviating from shareholders’ pre-emptive rights by arguing that the directed placement, which carries no warrants or manager fees and was priced in line with the earlier offerings at only a small discount to market, provides additional capital with minimal dilution, strengthens the shareholder base, and extends the company’s financial runway, with the new shares expected to start trading on Euronext Oslo Børs around 11 February 2026.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA (circRNA) expression technology for use in gene and cell therapies. Its proprietary circVec platform, developed by subsidiary Circio AB in Stockholm, is designed to deliver significantly longer RNA half-life and higher protein expression than conventional mRNA-based viral and non-viral vectors, targeting applications across genetic medicine, cell therapy and chronic diseases. In parallel, the company continues to advance its legacy TG01 immuno-oncology peptide vaccine for RAS-mutated cancers through external academic and industry collaborations in ongoing clinical trials in Norway and the United States.
Average Trading Volume: 3,957,474
Current Market Cap: NOK209.1M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.